Manfred Welslau, MD: Ongoing Research on Biosimilar Rituximab

Manfred Welslau, MD, Onkologie Aschaffenburg, Germany, discusses ongoing research on biosimilar rituximab, Rixathon.


Well it's just a safety analysis, and it’s the first interim safety analysis of about 80 patients. Another study recruited in March, so we will get the information of 182 patients, and they are now recorded but they [have not] finished their therapy. So we expect the first efficacy results this year. We're looking for efficacy, complete remission, and after the end of the therapy, and the second endpoint with [progression-free survival, PFS) rate at 12 months. So we have to wait at least 1 more year to look at this point.